Siemens Healthineers Boosts Manipal Hospice (MHRC) Therapy Block with Major CSR Support
Siemens Healthineers supports Manipal Hospice Therapy Block
The Manipal Hospice and Respite Care was inaugurated in May 2025 by the Honble Justice Shri S Abdul Nazeer, His Excellency the Governor of Andhra Pradesh, and was operational from June 2025.
The Therapy Block at MHRC is a 6,100-square-foot facility, which has been meticulously designed to provide comprehensive rehabilitative and supportive care, featuring dedicated spaces for physiotherapy, occupational therapy, mind-body therapy, speech and swallow therapy, home-based occupational therapy, and counseling. The Therapy Block aims to enhance the comfort, independence, and dignity of patients, addressing their physical, cognitive, and emotional needs.
Speaking on the collaboration, Hariharan Subramanian, Managing Director of Siemens Healthcare Pvt Limited said, 'The Therapy Block at the Manipal Hospice and Respite Centre, a pioneering hospice care initiative in India, addresses critical unmet needs of terminally ill patients. Our collaboration with MAHE to establish this therapy block reflects our shared commitment to fostering positive health outcomes and enhancing societal well-being within the communities we serve.'
Driving Impact Through Collaboration
This contribution is part of Siemens Healthineers' broader vision to pioneer breakthroughs in healthcare for everyone, everywhere. The company's partnership with Manipal Academy of Higher Education (MAHE) exemplifies the impact of industry-academia collaboration in transforming care delivery and supporting healthcare providers across the patient care continuum-from prevention and early detection to diagnosis, treatment, and aftercare.
Applauding collaboration with Siemens Healthineers' on this high-impact social initiative Lt Gen (Dr) MD Venkatesh, VSM (Retd) Vice Chancellor of MAHE, stated, 'MHRC is a pathbreaking initiative that advances our mission to deliver specialized, empathetic, and academically rooted healthcare. The support from Siemens Healthineers and other partners has been instrumental in realizing this vision.'
Manipal Hospice and Respite Centre, a 100-bed facility spread over 12 acres, is the first hospice in India to be affiliated with both a hospital and a university. It is the second largest hospice in India and aims to serve both patients with cancer and non-cancer. This hospice offers respite care as well as end-of-life care for both adults and children.
About Siemens Healthineers
Siemens Healthineers pioneers' breakthroughs in healthcare. For everyone. Everywhere. Sustainably. The company is a global provider of healthcare equipment, solutions and services, with activities in more than 180 countries and direct representation in more than 70. The group comprises Siemens Healthineers AG, listed as SHL in Frankfurt, Germany, and its subsidiaries. As a leading medical technology company, Siemens Healthineers is committed to improving access to healthcare for underserved communities worldwide and is striving to overcome the most threatening diseases. The company is principally active in the areas of imaging, diagnostics, cancer care and minimally invasive therapies, augmented by digital technology and artificial intelligence. In fiscal 2024, which ended on September 30, 2024, Siemens Healthineers had approximately 72,000 employees worldwide and generated revenue of around €22.4 billion. Further information is available at www.siemens-healthineers.com
Siemens Healthineers in India has a countrywide sales network and round-the-clock service set-up, two manufacturing facilities at Vadodara for Diagnostics and at Bengaluru for Medical Imaging Products, backed by a state-of-the-art R&D center as well as a global software development center at Bengaluru. With over 7,000 employees across the nation, Siemens Healthineers is playing a significant role in transforming care delivery in India and supporting healthcare providers across the entire range of patient care-from prevention and early detection to diagnosis, treatment, and aftercare. Further information is available at www.siemens-healthineers.co.in.
About Manipal Academy of Higher Education
The Manipal Academy of Higher Education (MAHE) is an Institution of Eminence Deemed-to-be University. MAHE offers over 400 specializations across the Health Sciences (HS), Management, Law, Humanities & Social Sciences (MLHS), and Technology & Science (T&S) streams through its constituent units at campuses in Manipal, Mangalore, Bengaluru, Jamshedpur, and Dubai. With a remarkable track record in academics, state-of-the-art infrastructure, and significant contributions to research, MAHE has earned recognition and acclaim both nationally and internationally. In October 2020, the Ministry of Education, Government of India, awarded MAHE the prestigious Institution of Eminence status. Currently ranked 4th in the National Institutional Ranking Framework (NIRF), MAHE is the preferred choice for students seeking a transformative learning experience and an enriching campus life, as well as for national & multi-national corporates looking for top talent.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indian Express
a few seconds ago
- Indian Express
Gujarat to prepare SOPs to stop duplicate, fake medicines from entering state
The Gujarat government, in a statement on Tuesday, said it is in the process of formulating Standard Operating Procedures (SOPs) to enhance detection and seizures of duplicate and fake medicines from entering the state. 'Recently, it came to the notice of the state government that fake medicines are entering (Gujarat). They are being sourced from outside the state and sold in some places inside the state. Gujarat's Food and Drug Control Administration (FDCA) has also taken action by conducting on-site inspections. To make this more stringent and strict, the government will prepare an SOP for the inspection of medicines coming from outside the state into Gujarat,' Health Minister Rushikesh Patel was quoted as saying. The SOPs would make registration of imported medicines mandatory, require registration of transporters carrying medicines and cancellation of licenses of chemists or wholesalers who are caught in such dealing with fake medicines. The SOPs will also require people to strictly follow the Drugs and Cosmetics Act. Besides, expensive and 'fast-moving' medicines will be closely monitored. The state government will also start three new testing labs in addition to the existing NABL-certified laboratory in Vadodara. To intensify on-site testing, 10 sets of state-of-the-art hand-held devices (Raman Spectrometer with Advanced Technology) will be purchased. Further, a flying squad will be formed. Patel added that with the implementation of these SOPs, Gujarat will become the first state in the country to adopt 'zero-tolerance' towards duplicate and fake medicines. 'The government will take intensive action to prevent fake/spurious/counterfeit medicines from outside the state in Gujarat. In the last 4 years, raids were conducted to prevent counterfeit medicines/cosmetics in the state and more than Rs 6 crore (worth of) medicines/cosmetics were seized…about 75 persons/firms were found involved and action was taken against them,' a statement read. Speaking about the type of activities unearthed so far, the statement said, 'In most of these cases, persons who do not have a valid license for buying, selling and storing medicines are involved and investigation has also revealed that in most of the cases, counterfeit medicines come from outside the state.'
Time of India
an hour ago
- Time of India
SME IPO: Medistep Healthcare's Rs 16-cr public issue to open on Aug 8
Pharmaceutical firm Medistep Healthcare is set to raise a little over Rs 16 crore through its initial public offering ( IPO ), which opens for subscription on August 8. The company's maiden public issue will conclude on August 12. The shares are scheduled to be listed on the NSE SME platform on August 18, Medistep Healthcare said in a statement. Productivity Tool Zero to Hero in Microsoft Excel: Complete Excel guide By Metla Sudha Sekhar View Program Finance Introduction to Technical Analysis & Candlestick Theory By Dinesh Nagpal View Program Finance Financial Literacy i e Lets Crack the Billionaire Code By CA Rahul Gupta View Program Digital Marketing Digital Marketing Masterclass by Neil Patel By Neil Patel View Program Finance Technical Analysis Demystified- A Complete Guide to Trading By Kunal Patel View Program Productivity Tool Excel Essentials to Expert: Your Complete Guide By Study at home View Program Artificial Intelligence AI For Business Professionals Batch 2 By Ansh Mehra View Program The IPO comprises 37.44 lakh equity shares priced at a fixed Rs 43 per share, aggregating to a total issue size of Rs 16.09 crore. Following the listing, the company is expected to have a market capitalisation of Rs 61.10 crore. The company will utilise the proceeds of the IPO for purchase of plant and machinery for expansion of its existing manufacturing facility, working capital requirements and general corporate purposes. "Proceeds from the IPO will strategically support our expansion efforts and reinforce our footprint in both domestic and international markets," Girdhari Lal Prajapati, Managing Director at Medistep Healthcare, said. Live Events The company is in the business of manufacturing sanitary pads & energy powder, and trading of a diverse range of pharmaceutical products, nutraceutical products, intimate products and surgical products through a distribution network. On the financial front, the company recorded revenue from operations of Rs 49.65 crore in FY25, an increase from Rs 39.07 crore in the preceding fiscal. Its profit after tax (PAT) also rose to Rs 4.14 crore in FY25, compared to Rs 3.33 crore in the previous financial year. Fast Track Finsec is the sole lead manager of the public issue while Cameo Corporate Services is the registrar to the issue.
&w=3840&q=100)
Business Standard
3 hours ago
- Business Standard
Eris Lifesciences to tap Rs 5,000-cr insulin and semaglutide market in FY26
Ahmedabad-based Eris Lifesciences is looking to tap opportunities in the nearly Rs 5,000-crore Indian insulin market after Danish drugmaker Novo Nordisk announced the withdrawal of its insulin products from the market in April this year. 'We expect that Novo's cartridge inventory in the market will run out by October 2025. So this market opportunity is something that one can start monetising from the November–December time frame,' the company's executive director and chief executive officer (CEO), Krishnakumar Vaidyanathan, told Business Standard. He added that the timing fits Eris' plans, as the cartridge filling capability of its Bhopal unit will start becoming operational from January. Vial manufacturing has already been commissioned at the unit, with the company creating a strategic stock of insulins. This comes at a time when Eris is already the largest domestic player in insulins. The company had acquired the India formulations business of Biocon Biologics last year — including established insulin brands Basalog and Insugen. 'Before the Biocon deal, we had a couple of homegrown insulin brands in the market, which did a combined Rs 60 crore in revenue last year. Basalog and Insugen had combined revenues of Rs 200 crore at the time of acquisition,' he said. He added that, with this, the company's insulin franchise has become significantly larger, with a 10 per cent market share. Eris is also among the prominent drugmakers looking to roll out generic versions of the blockbuster molecule semaglutide once its patent expires around March next year. Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist used as an active pharmaceutical ingredient in medications for obesity management and Type-II diabetes. According to Eris' investor presentation for the June quarter of 2025–26 (Q1FY26), the company is on track to be among the first launches in India in March 2026. The company has initiated validation of synthetic semaglutide cartridges at its European Union (EU)-approved AMD injectables site. 'We are also planning the validation of the recombinant semaglutide in our Bhopal plant later this year,' he added. As far as the go-to-market strategy is concerned, the company said it is already in a strong position because of its dominant presence in insulins and prior presence in the GLP market with the launch of liraglutide in September last year. For Q1FY26, Eris Lifesciences recorded a 40 per cent year-on-year (Y-o-Y) rise in consolidated profit after tax (PAT) to Rs 125 crore. Revenue rose to Rs 773 crore during the June quarter against Rs 720 crore in the year-ago period.
